Cannabis Science, Inc. Selects Product for FDA Testing
Press release: 04/09/09 Gulf Onshore Announces Name Change.
Gulf Onshore Announces Name Change to Cannabis Science, Inc. and Selection of Its First Pharmaceutical Cannabis Product for FDA Testing
ADDISON, Texas–(BUSINESS WIRE)–Gulf Onshore Inc (OTCBB: GFON.OB) has changed its name to Cannabis Science, Inc., reflecting its new business mission, and has requested a new stock trading symbol, which will be will be assigned by NASDAQ OMX in the near future. Cannabis Science Inc. has also launched its new website www.cannabisscience.com reflecting its new name.
The Company’s first pharmaceutical cannabis product for DHHS- and FDA-qualified testing will be a whole-cannabis extract in the form of a lozenge. The Company has applied for its DEA handling license and is interviewing researchers to complete and sponsor its IND (Investigational New Drug) test protocols.
The lozenge is a part of the assets and know-how developed by Steven W. Kubby and Dr. Robert J. Melamede and acquired by the Company from Cannex Therapeutics of California.
Initial findings from informal human trials using the whole-cannabis extract demonstrate the lozenge has the capacity to enhance rapid onset through oromucosal absorption. Last year, an early version of the lozenge was tested at Vancouver Island Compassion Society (VICS) (www.thevics.com), a non-profit medical cannabis organization located in Victoria, B.C, which is at the forefront of this patient-centered approach to cannabis research.


